Cambridge, MA, March 15, 2017 -- Aurora BioPharma, Inc., a clinical stage biotechnology company developing CAR T Cell Therapy to treat Solid and Liquid tumors, announced today that company CEO and President, Robert Brooks, will attend the Oppenheimer & Co. 27th Annual Healthcare Conference on March 21-22, 2017 at The Westin New York Grand Central in New York City. The event is one of the most important investor conferences in the healthcare industry. Investors will have access to and be able to gain insight from key thought leaders from public and private companies spanning all major sectors: bio & specialty pharmaceuticals; medical devices; healthcare facilities; life science tools and diagnostics; healthcare information technology and distribution, and healthcare providers. Company executives will address topical issues such as health reform; generic drug regulation; development of new pharmaceutical and biotechnology products; product safety, patent issues and Food and Drug Administration policy.
Oppenheimer & Co., Inc. ("Oppenheimer") is a leading investment bank and full-service investment firm that provides financial services and advice to high net worth investors, individuals, businesses and institutions. For over 130 years, they have provided investors with the necessary expertise and insight to meet the challenge of achieving their clients' financial goals. Oppenheimer is a wholly owned subsidiary of Oppenheimer Holdings Inc., an integrated financial services holdings company. Oppenheimer Holdings Inc.'s other wholly owned subsidiaries include Oppenheimer Asset Management Inc., Oppenheimer Life Agencies Ltd., and Oppenheimer Trust Company of Delaware.
Aurora is leading in the development of Chimeric Antigen Receptor (CAR) T therapy, with an extensive clinical pipeline. Osteosarcoma is the most common type of bone cancer in Children and Adolescents, even after radical amputation of a limb and chemotherapy, survival is poor. A completed Phase I/IIa trial in 19 Sarcoma (16 Osteosarcoma) patients was completed, Aurora's CAR T agent AU-101 met its endpoints of safety, with strong signs of tumor killing efficacy, and long term survivors. Glioblastoma is the most common and deadliest form of brain cancer. Aurora's CAR T agent AU105 showed in a completed Phase I/IIa clinical trial in 16 Glioblastoma patients, safety, tumor killing efficacy, and double the median historic overall survival. Aurora is planning a randomized multi-site Phase II trial of AU105 in Early Diagnosed Glioblastoma, and a Phase I/II trial in Recurrent Glioblastoma with intracranial injection. Aurora is planning a Phase II trial of its CAR T Cell therapy AU105 in Osteosarcoma.
Internet: www.aurora-biopharma.com
The electronic message you received is confidential and may be legally privileged or otherwise protected from disclosure. If you are not the intended recipient, please call or email the sender and delete this message and any attachment from your system; you must not copy or disclose the contents of this message or any attachment to any other person.
This is not an offer or a solicitation of an offer to purchase or sell any security. Statements in this message that are not based on historical or current facts, including without limitation statements such as the words "anticipates," "believes," "may," "continues," "estimates," "expects," and "will" constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward- looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Although Aurora BioPharma, Inc. believes that expectations conveyed by the forward-looking statements are reasonable based on the information available to it on the date such statements were made, no assurances can be given as to the future results, approvals or achievements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements, and should assume the Company has no obligation to update forward-looking statements except as otherwise required by applicable law.
Candace Cobos
Aurora BioPharma, Inc.
Tel: (617) 674-7718 - Fax: (617) 674-7701
candace.cobos@aurora-biopharma.com
SOURCE Aurora BioPharma, Inc.